Electra's Bid to Reach $977. 6M: A Cautionary Tale of Biotech Boom and Bust The latest biotech IPO from Silicon Valley, Electra Therapeutics, seeks a valuation of up to $977. 6 million in its US listing.
On the surface, this may seem like another success story of innovation and risk taking in the healthcare sector.
However, scratch beneath the veneer, and you'll find a narrative that echoes the boom and bust cycle characteristic of biotech's relationship with Wall Street. Electra is seeking to raise as much as $346.